Eversept Partners’s Cullinan Oncology CGEM Stock Holding History

Eversept Partners’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-163,880	Closed	-$4.22M	–	110
2021 Q2	$4.22M	Buy	+163,880	New	+$5.04M	0.28%	51

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Eversept Partners's CGEM Position: Q3 2021 in Review

Eversept Partners sold out of Cullinan Oncology (CGEM) in Q3 2021, closing a stake of 163,880 shares — an estimated $4.22M sold.

Eversept Partners first reported a position in CGEM in Q2 2021 and held it in 1 quarter. The position peaked at $4.22M in Q2 2021. 66 funds tracked by Wall St. Rank hold CGEM as of Q3 2021.

Eversept Partners reported no remaining Cullinan Oncology position as of Q3 2021 after selling out during the quarter.
Eversept Partners sold 163,880 Cullinan Oncology shares in Q3 2021, an estimated $4.22M.
Eversept Partners first reported a position in Cullinan Oncology in Q2 2021 and held it in 1 quarter.
Eversept Partners's Cullinan Oncology position peaked at $4.22M in Q2 2021.
66 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.